Blood Res.  2015 Dec;50(4):254-256. 10.5045/br.2015.50.4.254.

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin

• Kim HK
• Moon SM
• Moon JH
• Park JE
• Byeon S
• Kim WS

• KMID: 2133761
• DOI: http://doi.org/10.5045/br.2015.50.4.254

Abstract

No abstract available.

MeSH Terms

Lymphoma*

Figure

• 

  Fig. 1 (A, B) Multiple ulcerative skin lesions before treatment with brentuximab vedotin. Positron emission tomography (PET) scan (C) before, and (D) after 4 cycles of treatment with single-agent brentuximab vedotin.

• 

  Fig. 2 Pathology images of the skin biopsy showing extranodal NK/T-cell lymphoma (ENKL). (A) Positive staining for CD3 in lymphoma cells (×400 magnification). (B) Positive staining for CD30 in lymphoma cells (×400 magnification). (C) In situ hybridization of Epstein-Barr virus, showing positive cells (×400 magnification).

Reference

1. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008; 99:1016–1020. PMID: 18294294.

2. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363:1812–1821. PMID: 21047225.

3. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30:2190–2196. PMID: 22614995.

4. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123:3095–3100. PMID: 24652992.

5. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005; 19:2186–2194. PMID: 16179910.

6. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995; 85:1–14. PMID: 7803786.

7. Hong J, Park S, Baek HL, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol. 2012; 5:939–947. PMID: 23119111.

8. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013; 121:4997–5005. PMID: 23652805.

9. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011; 17:6428–6436. PMID: 22003070.